These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 32433641)
1. Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19. Furuhashi M; Moniwa N; Takizawa H; Ura N; Shimamoto K Hypertens Res; 2020 Aug; 43(8):837-840. PubMed ID: 32433641 [No Abstract] [Full Text] [Related]
2. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. Vaduganathan M; Vardeny O; Michel T; McMurray JJV; Pfeffer MA; Solomon SD N Engl J Med; 2020 Apr; 382(17):1653-1659. PubMed ID: 32227760 [No Abstract] [Full Text] [Related]
3. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis. Guo X; Zhu Y; Hong Y Hypertension; 2020 Aug; 76(2):e13-e14. PubMed ID: 32458694 [No Abstract] [Full Text] [Related]
4. The Renin-Angiotensin-Aldosterone System in Coronavirus Infection-Current Considerations During the Pandemic. Augoustides JGT J Cardiothorac Vasc Anesth; 2020 Jul; 34(7):1717-1719. PubMed ID: 32360010 [No Abstract] [Full Text] [Related]
5. Drugs and the renin-angiotensin system in covid-19. Aronson JK; Ferner RE BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880 [No Abstract] [Full Text] [Related]
6. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension? Huang Y; Xie C; Chen X; Hong Q; Huang H Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834 [No Abstract] [Full Text] [Related]
7. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? Patel AB; Verma A JAMA; 2020 May; 323(18):1769-1770. PubMed ID: 32208485 [No Abstract] [Full Text] [Related]
8. Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19. Megaly M; Glogoza M Scott Med J; 2020 Nov; 65(4):123-126. PubMed ID: 32807019 [TBL] [Abstract][Full Text] [Related]
9. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury. Sarzani R; Giulietti F; Di Pentima C; Giordano P; Spannella F Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L325-L336. PubMed ID: 32639866 [TBL] [Abstract][Full Text] [Related]
10. Associations Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality Among Patients With COVID-19. Tan ND; Qiu Y; Xing XB; Ghosh S; Chen MH; Mao R Gastroenterology; 2020 Sep; 159(3):1170-1172.e1. PubMed ID: 32422208 [No Abstract] [Full Text] [Related]
11. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? Sommerstein R; Kochen MM; Messerli FH; Gräni C J Am Heart Assoc; 2020 Apr; 9(7):e016509. PubMed ID: 32233753 [No Abstract] [Full Text] [Related]
12. [Renin-angiotensin system blockers and COVID-19 infection]. Ruilope LM; Garcia Donaire JA; de la Sierra A Hipertens Riesgo Vasc; 2020; 37(3):99-100. PubMed ID: 32448641 [No Abstract] [Full Text] [Related]
13. Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study. Conversano A; Melillo F; Napolano A; Fominskiy E; Spessot M; Ciceri F; Agricola E Hypertension; 2020 Aug; 76(2):e10-e12. PubMed ID: 32383626 [No Abstract] [Full Text] [Related]
14. Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers: A Comparison of Outcomes in Patients With COVID-19. Kalra A; Hawkins ES; Nowacki AS; Jain V; Milinovich A; Saef J; Thomas G; Gebreselassie SK; Karnik SS; Jehi L; Young JB; Svensson LG; Chung MK; Mehta N Circ Cardiovasc Qual Outcomes; 2020 Oct; 13(10):e007115. PubMed ID: 32856462 [No Abstract] [Full Text] [Related]
15. [The RAAS and SARS-CoV-2: A riddle to solve]. Choi M; Aiello EA; Ennis IL; Villa-Abrille MC Hipertens Riesgo Vasc; 2020; 37(4):169-175. PubMed ID: 32527699 [TBL] [Abstract][Full Text] [Related]
16. Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis. Greco A; Buccheri S; D'Arrigo P; Calderone D; Agnello F; Monte M; Milluzzo RP; Franchina AG; Ingala S; Capodanno D Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):335-337. PubMed ID: 32671399 [No Abstract] [Full Text] [Related]
17. Related molecular mechanisms of COVID-19, hypertension, and diabetes. Akkus E; Sahin M Am J Physiol Endocrinol Metab; 2020 Jun; 318(6):E881. PubMed ID: 32479159 [No Abstract] [Full Text] [Related]
18. Renin-Angiotensin System Blockade and Mortality in Patients With Hypertension and COVID-19 Infection. Salah HM; Calcaterra G; Mehta JL J Cardiovasc Pharmacol Ther; 2020 Nov; 25(6):503-507. PubMed ID: 32748634 [TBL] [Abstract][Full Text] [Related]
19. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. Rossi GP; Sanga V; Barton M Elife; 2020 Apr; 9():. PubMed ID: 32250244 [TBL] [Abstract][Full Text] [Related]